ReadyRx Review: The $130 NAD+ Price Is a First Month

ReadyRx (readyrx.com) does something most compounded NAD+ sellers do not: it publishes a real price table. Two vial sizes for the injection, a bottle size for the nasal spray, two plan lengths, and a separate first-month and standing figure for every one of them.¹ You can read the whole thing without starting an intake, which is more than several of the providers on our NAD+ price index will let you do.

The headline number is the smallest cell in that table, and it is not a monthly rate.

The number on the front of the site

Every entry point says from $130 a month. The homepage says it. The treatments page says it. The NAD+ page's own hero says "From $130" with $190 struck through beside it.

$130 is the cheapest product, on the longest prepayment, in the first month only. Three separate discounts folded into one figure. Here is the table underneath it.

What you actually end up paying

Follow any row across. If you buy the 500 mg injection month to month — no commitment, cancel whenever — you pay $170 once and $190 every month after that. That is the standing rate, and it is $60 above the advertised floor.

If you take the quarterly plan to reach $130, the site's own footnote tells you what you have agreed to, in one line under the table: "Price shown applies to quarterly plans paid up-front." So the $130 is not a monthly bill either. It is the first month's share of a block you pay for in a single charge, and from month two that same plan bills $150. There is no plan on this site, at any length, on which $130 is what you pay in a typical month.

We file ReadyRx at $190 a month for the 500 mg injection, because that is the rate a reader who buys the no-commitment option is actually on. The most common way a provider ends up looking cheapest on a price comparison is not that it is cheapest — it is that somebody filed a promotional month, or a prepay rung, or both at once, as a monthly medication price. This one is both at once.

A banner across the top adds "Extra $20 Off" with a promo code, which moves the first month again and the standing rate not at all. Introductory pricing is not dishonest and ReadyRx discloses its standing rates plainly a few inches below the headline. But the number that travels — into ads, into newswire write-ups, into the figure you remember — is $130, and $130 is a rate nobody pays twice.

What the milligrams buy

Because the sizes are published you can do arithmetic here that several rows on our index do not permit. The injection comes as a 500 mg or a 1,000 mg vial. The nasal spray is a 15 mL bottle, and the site's own dosing answer puts it at 4,500 mg — which works out to 300 mg per milliliter.

That last figure is worth holding onto, because it makes the nasal spray directly comparable to something. Auren Rx's 300 mg/mL, 15 mL nasal option is $189 a month with no commitment; ReadyRx's 300 mg/mL, 15 mL bottle is $190. Same strength, same volume, a dollar apart. When two sellers land within a dollar on an identical spec, you are looking at a category price rather than a bargain either one found.

Resist taking that arithmetic any further than the price. Cost per milligram is a real comparison inside a single route and against the same route elsewhere. It is not a measure of how much NAD+ reaches your bloodstream, because for these routes nobody has measured that in a person. Our route-by-route breakdown works through why the absorption ranking people repeat does not survive contact with the outcome data.

The Alzheimer's answer on the product page

This is the part of the site we would most want a reader to see before the price.

Open the frequently-asked questions on the NAD+ product page and one of the headings is "Can NAD+ help prevent Alzheimer's disease?" The answer describes a study in which NAD+ supplementation normalized several disease-related features — synaptic plasticity, learning and memory deficits, DNA damage responses.

Every word of that is accurate about the study. The study is in mice.² Specifically, it is a mouse model of Alzheimer's disease engineered to carry a DNA repair deficiency, published in 2018, and it is a legitimate piece of laboratory neuroscience. It is not evidence that a subscription nasal spray or a home injection changes anyone's odds of dementia, and the page does not say the word "mice".

Putting a dementia question on a product page and answering it with an animal model is the single most consequential thing on this site, and it sits below a checkout button. To the company's credit, the question is phrased as a question and the answer is hedged with "some studies suggest". That is not enough. A reader scanning for whether this helps a parent will take the shape of the answer, not its qualifiers.

What stands behind the two routes it sells

For injected NAD+, there is no randomized human trial and no published pharmacokinetic study of the subcutaneous route. The one human study of administered NAD+ we can point to is a small pilot in which participants received a six-hour intravenous infusion, and it measured the plasma and urine metabolome rather than any clinical outcome.³ Injection is not infusion, and even the infusion literature stops there. The injection evidence file has the long version.

For intranasal NAD+, the supporting studies are rodent models of stroke and traumatic brain injury.⁴⁵ They are real experiments, and they are not evidence that a spray raises NAD+ in a healthy adult; nose-to-brain delivery remains an open research problem rather than a solved one.⁶ See whether it absorbs through the nose.

What does have controlled human data is the oral precursor. Nicotinamide riboside is orally bioavailable and raises blood NAD+ in people,⁷ reliably and over months of dosing.⁸ Even there the benefits are the weak part: a systematic review of precursor trials found the metabolic effects limited and inconsistent despite the biomarker rising.⁹ Compounded NAD+ is not an FDA-approved drug for any indication, and that is true of every seller in this category rather than this one in particular.

Who is behind it, and what is missing

ReadyRx publishes its prices better than it publishes itself.

No pharmacy is named. The product FAQ says medications are sourced through "FDA-registered, U.S.-based compounding pharmacies" and the terms refer only to "the Pharmacies" as a defined class. For a compounded product, where sterility and dosing accuracy live entirely with the compounder, that is the disclosure that matters most, and no facility appears on any of the eleven pages we opened.

No prescriber is named. The site says treatment plans are reviewed by "licensed, board-certified clinicians". No individual, no credential, no NPI, and no medical group is identified anywhere, so nothing here can be checked against the national provider registry.

No state list. The terms say you must be located in the same state as your shipping address when you consult, and that the service is subject to state regulations. Which states, it never says. There is no about page and no states page — both return a not-found. You learn whether you are eligible by starting an intake, after you have handed over a medical history.

And the site names two different companies as its operator. The Terms of Use, last modified in June 2026, say Ready Health Ventures Inc. owns and operates readyrx.com. The privacy, cookie and communication policies, all last modified in April 2024, say Executive Medical, LLC controls the site. The contact form's message consent names Ready Health Ventures Inc. Both are plausibly the same business under a new name with stale policy documents behind it, which is the ordinary explanation and probably the right one. It is still the case that a reader trying to work out who is on the other side of the transaction gets two answers from the same company on the same afternoon. Governing law is Tennessee.

The terms worth reading before the price

All sales are final. The refund section says so in capitals, and then that returns and refunds are not accepted once an order has been processed, shipped or delivered. Partially used subscription periods are not refunded, though the company may make exceptions at its discretion.

Cancellation is by email only — support@readyrx.com — takes effect at the end of the current period, and must reach them at least four business days before the renewal processing date. Miss that window and you have bought another cycle. On the quarterly plan, that cycle is a prepaid block.

Your first renewal may be charged early, in the terms' own words, and later shipments may be charged and shipped up to three days early. Nothing about that is hidden, and all of it argues for putting the cancellation deadline in a calendar the day you sign up rather than the day you want out.

Where it lands

ReadyRx publishes more of its price structure than most of the sellers we track, and if you read the table instead of the headline you will know exactly what you are agreeing to. The 500 mg injection is $190 a month with no commitment; the nasal spray is $190 for a 15 mL, 4,500 mg bottle; the quarterly plans are real and cheaper and are paid in a lump. Nothing in that structure is a trick. The headline drawn from it is.

What the money buys is a delivery route with no human pharmacokinetic study behind it, sold on a page that answers a question about Alzheimer's disease with a mouse. Weigh that against the disclosure gaps — no pharmacy, no prescriber, no states, two operator names — before you weigh it against anyone's price. The comparable operators we have read are Auren Rx, which publishes seven rungs with strengths and volumes on each, Pepti, which sells three routes and names no pharmacy either, and Trellis Vitality, whose flagship has no ladder at all.

Then ask the prior question, which no price on this page answers: whether you want this route at all. The cheapest approach with controlled human evidence behind it is still an oral precursor at a fraction of any figure here — is NAD+ therapy worth it, is nicotinamide riboside worth it and NMN vs NR work through it. Providers we do have a commercial relationship with are ranked and disclosed on our NAD+ rankings hub.